| 25th week of 2009 patent applcation highlights (06-18-09/06-18-09_39) part 39 |
| Patent application number | Title | Published |
|---|
| 20090155284 | HGF-SF MONOCLONAL ANTIBODY COMBINATIONS - The present invention provides a combination of anti-HGF/SF antibodies that specifically bind HGF/SF and inhibits HGF/SF activity. The present invention further provides a combination of anti-HGF/SF antibodies comprising three or more anti-HGF/SF antibodies selected from the group consisting of: antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B10, antibody #5 produced from hybridoma 13B1-E4-E10, antibody #7 produced from hybridoma 15D7-B2, and antibody #10 produced from hybridoma 31D4-C9-D4. The invention also provides a method of treating cancer in a subject comprising administering to the subject a combination of anti-HGF/SF antibodies whereby the antibodies bind to a hepatocyte growth factor, whereby the binding of the antibodies to a hepatocyte growth factor results in an inhibition of hepatocyte growth factor binding to the hepatocyte growth factor receptor, whereby the inhibition of hepatocyte growth factor binding to receptor causes an inhibition of cancer growth, thereby treating the cancer. | 06-18-2009 |
| 20090155285 | TGF-BETA BINDING ANTIBODIES - The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal. | 06-18-2009 |
| 20090155286 | Type I interferon blocking agents for prevention and treatment of psoriasis - The discovery of plasmacytoid dendritic cell precursors (PDC) as crucial effector cells with high production of type I interferons (IFNs) in early psoriasis development has led to the present invention that blocking of type I IFNs can be used for prevention and therapy of psoriasis. The invention relates to the use of a type I interferon blocking agent, such as a type I IFN antagonist (e.g. an anti-IFN-α antibody) or type I IFN receptor antagonist, for the preparation of a medicament for the prevention and treatment of psoriasis, and to a method of prevention and treatment of psoriasis using a type I interferon blocking agent. | 06-18-2009 |
| 20090155287 | Modified vaccinia virus strains for use in diagnostic and therapeutic methods - Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including cancer, and as anti-tumor and/or antiangiogenic agents. The viruses also can be used in diagnostic methods. | 06-18-2009 |
| 20090155288 | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies - A method of identifying a combination of antibodies with a combined improved anti tumor activity is provided. The method comprising identifying at least two anti RTK antibodies capable of inducing synergistic endocytosis of the RTK in a cell expressing the RTK, thereby identifying the combination of antibodies with the combined improved anti-tumor activity. | 06-18-2009 |
| 20090155289 | FURIN-CLEAVABLE PEPTIDE LINKERS FOR DRUG-LIGAND CONJUGATES - Disclosed are certain peptide linkers for conjugating drugs to ligands, and the resulting drug-linker-ligand molecules and compositions thereof. The conjugated molecules useful for the targeted delivery of drugs to the desired cells, and allow for the intracellular release of the drug in cases where the targeted antigen is internalized via the trans Golgi network and not the lysosomal pathway. | 06-18-2009 |
| 20090155290 | Antigen - The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described. | 06-18-2009 |
| 20090155291 | METHOD OF INCREASING IMMUNOLOGICAL EFFECT - A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune production, blocking immune destruction, and increasing immunological effect in the patient. Methods of treating an immune target, treating a tumor, immune prophylaxis, and preventing tumor escape. | 06-18-2009 |
| 20090155292 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS - The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases. | 06-18-2009 |
| 20090155293 | MODIFIED DEFENSINS AND THEIR USE - This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. In one embodiment, compositions including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. In one embodiment, a method is provided for modulating an antimicrobial activity. In another embodiment, a method if provided for inhibiting a cytotoxic activity. Also disclosed are methods for treating diseases in a subject that are associated with an immune response, such as inflammatory and pulmonary diseases, using the disclosed modified defensin polypeptides. | 06-18-2009 |
| 20090155294 | HCV VACCINES - Disclosed are methods and compositions for inducing immune responses against Hepatitis C virus (HCV). The compositions comprise one or more epitope from a hotspot epitope. In certain embodiments, an HCV vaccine comprising at least two epitopes, each from a different hotspot epitope, is provided. | 06-18-2009 |
| 20090155295 | VACCINE - A polypeptide derived from the periplasmic space of | 06-18-2009 |
| 20090155296 | MUTANTS OF LYSINE DECARBOXYLASE, VACCINES FOR PERIODONTITIS, AND METHODS OF USE - The present invention is directed to mutants of lysine decarboxylase, nucleic acids encoding the mutants, and vaccines comprising the mutants for inhibiting and reducing the development of periodontal diseases, including gingivitis and chronic periodontitis. The vaccine composition comprises a recombinant lysine decarboxylase mutant which is based on a native version of the enzyme from | 06-18-2009 |
| 20090155297 | Methods and Compositions for Inducing an Immune Response Against Multiple Antigens - Methods and compositions for inducing an immune response against multiple antigens are provided herein. In one aspect, the invention provides a chimeric immunogen, comprising a receptor binding domain, a translocation domain, and more than one non-contiguous heterologous antigen. In other aspects, the invention provides nucleic acids encoding chimeric immunogens of the invention, kits comprising chimeric immunogens of the invention, cells expressing chimeric immunogens of the invention, and methods or using chimeric immunogens of the invention. | 06-18-2009 |
| 20090155298 | Matrix Metalloproteinase 11 Vaccine - Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid en->coding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy. | 06-18-2009 |
| 20090155299 | Antibodies for the Detection of Bacillus Anthracis and Vaccine Against B. Anthracis Infections - The present invention relates to conjugates of oligosaccharides of formula 1, wherein R is a linker to a carrier protein and optionally comprises up to three further saccharides, 5 and which are useful for vaccination, methods of synthesis of such conjugates, antibodies against this antigen, hybridoma producing monoclonal antibodies against this antigen, assays using these antibodies for the detection of | 06-18-2009 |
| 20090155300 | BASIDIOMYCETES, BASIDIOMYCETES EXTRACT COMPOSITION, HEALTH FOODS, AND IMMUNOPOTENTIATORS - Basidiomycetes which is a novel mushroom having an excellent immunopotentiating action, etc., a Basidiomycetes extract composition, and health foods and immunopotentiators using the Basidiomycetes extract composition are provided. | 06-18-2009 |
| 20090155301 | Pseudoinfectious flavivirus and uses thereof - The present invention discloses a replication-deficient pseudoinfective virus belonging to the Flaviviridae family that lack the capsid gene, where the replication-deficient pseudoinfective virus propagates only in cells expressing the capsid or capsid, prM and envelope protein of the flavivirus. The present also discloses the method of producing such viruses on a large scale and the use of these pseudoinfective viruses as vaccines for preventing diseases caused by infections of humans or animals by the viruses belonging to this family. | 06-18-2009 |
| 20090155302 | Antigen Arrays for Treatment of Allergic Eosinophilic Diseases - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an array comprising a protein or peptide of IL-5, IL-13 or eotaxin. More specifically, the invention provides a composition comprising a virus-like particle and at least one protein, or peptide of IL-5, IL-13 and/or eotaxin bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of allergic diseases with an eosinophilic component and as a pharmaccine to prevent or cure allergic diseases with an eosinophilic component and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. | 06-18-2009 |
| 20090155303 | CPG SINGLE STRAND DEOXYNUCLEOTIDES FOR USE AS ADJUVANT - The present invention provides an adjuvant, which includes at least one single strand deoxynucleotide containing a CpG dinucleotide. The single strand deoxynucleotide comprises one or more CpG dinucleotides. When used in combination with rabies vaccine, HBV vaccine or other vaccines, the adjuvant can significantly improve the immune effect of the vaccine. | 06-18-2009 |
| 20090155304 | Modified Cyanovirin-N Polypeptide - This disclosure relates to a modified version of cyanovirin-N protein and a transformed | 06-18-2009 |
| 20090155305 | Manufacture of Vaccines That Contain Both Hepatitis B Virus Surface Antigen and Surfactant - When preparing HBsAg for use in a combination vaccine, it is known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification. | 06-18-2009 |
| 20090155306 | Pamps, pathogen associated molecular patterns - A method for identifying a polypeptide which acts as an adjuvant in a host organism. The invention further provides adjuvant compositions comprising said polypeptides and optionally further comprising an antigen. | 06-18-2009 |
| 20090155307 | IMMUNOSTIMULATORY NUCLEIC ACID OIL-IN-WATER FORMULATIONS AND RELATED METHODS OF USE - The invention involves methods and compositions of an immunostimulatory nucleic acid in oil-in-water emulsions for topical delivery. The compositions can be used to stimulate immune responses, particularly useful in the prevention and/or treatment of infectious disease and cancer. | 06-18-2009 |
| 20090155308 | Powerful vaccine composition comprising lipopeptide and poly I:C as an adjuvant - The present invention relates to an adjuvant comprising a lipopeptide and poly I:C. When the adjuvant of the present invention is used, the level of antigen specific antibody induction is synergistically increased and Th1 type immune response is also induced. Therefore, the adjuvant of the present invention can be very effectively used as an adjuvant in the formulation of preventive and therapeutic vaccines for viral or parasitic infection and cancer. | 06-18-2009 |
| 20090155309 | Novel vaccine - The invention relates to the use of a non-live influenza virus antigen preparation, particularly a split influenza virus preparation, in the manufacture of a vaccine formulation for a one-dose intranasal vaccination against influenza, wherein the one-dose vaccination meets international regulatory requirements for influenza vaccines. Further provided are methods for the production of the vaccine, and a pharmaceutical kit comprising an intranasal administration device and the one-dose vaccine. | 06-18-2009 |
| 20090155310 | HN EPITOPE RECOGNIZED BY AVIAN IMMUNE SYSTEM AND ANTIGENIC VARIANT NEWCASTLE DISEASE VIRUSES CARRYING CHANGES IN THE EPITOPE - The present invention relates to an epitope of HN protein in Newcastle disease virus which can be recognized by an avian immune system and an antibody against the epitope, a method for detecting a Newcastle disease virus by using the antibody, and an antigenic variant of Newcastle disease virus carrying changes in the epitope. The epitope of HN protein and the antigenic variant of Newcastle disease virus can be used for developing efficient vaccines, and further, in diagnosing the Newcastle disease virus rapidly and exactly. | 06-18-2009 |
| 20090155311 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS - The present invention provides methods for the control of the generation of regulatory T cells (Tregs) and uses thereof. | 06-18-2009 |
| 20090155312 | VIRAL VARIANTS DETECTION AND APPLICATION - The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus. | 06-18-2009 |
| 20090155313 | Vaccine Against Salmonid Rickettsial Septicaemia Based on Arthrobacter Cells - A vaccine based on live | 06-18-2009 |
| 20090155314 | Dermal filler - Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin. | 06-18-2009 |
| 20090155315 | PHARMACEUTICAL PRODUCT - A pharmaceutical and pharmaceutical-like product is provided. The product provides a plurality of components having active agents that are delivered in a single delivery entity or vehicle. The product allows for selective control of the release rates of each of the active agents while still being delivered in a single product. | 06-18-2009 |
| 20090155316 | Oral Wash - An oral wash comprising an aqueous dispersion of transition metal fineparticles such as platinum colloid. The wash is capable of conveniently and quickly eliminating active oxygen species which causes damages of mucosa in the oral cavity, periodontium, and the like. | 06-18-2009 |
| 20090155317 | COSMETIC OR DEMOPHARMACEUTICAL COMPOSITION COMPRISING ENKEPHALIN-DERIVED PEPTIDES TO REDUCE AND/OR ELIMINATE FACIAL WRINKLES - The invention relates to a cosmetic or dermopharmaceutical composition comprising enkephalin-derived peptides for reducing and/or eliminating facial wrinkles. Said cosmetic or dermopharmaceutical composition for application in the skin, preferably in the skin of the face, to reduce and/or eliminate facial wrinkles, preferably facial expression wrinkles and comprises a cosmetically or dermopharmaceutically effective amount of a peptide of general formula (I). | 06-18-2009 |
| 20090155318 | PROCESS TO FORM NANO-SIZED MATERIALS, THE COMPOSITIONS AND USES THEREOF - Various embodiments of the invention include systems and methods of generating nano-sized salt particles. These methods include generation of a supersaturated solution of a salt MX by mixing of salts MY and NX in which the solubility of MX is lower than that of MY, NX or NY. In some embodiments, nano-sized particles of MX are grown further by further adiabatic addition of salts MY and/or NX. In some embodiments, MX includes potassium nitrate. Some embodiments include compositions of MX configured for use in treatment of dentine sensitivity. | 06-18-2009 |
| 20090155319 | METHOD FOR PRODUCING COSMETIC AND/OR DERMATOLOGICAL POWDER - A cosmetic or dermatological powder, which comprises (i) from 61 to 99.99% by weight is relative to the total weight of the powder of at least one starch modified by a combination of esterification and heat-moisture treatment, (ii) from 0.01 to 29.99% by weight is relative to the total weight of the powder, of an oily phase comprising at least one oil. | 06-18-2009 |
| 20090155320 | Method for producing hydroxyapatite particles - This invention relates generally to a preparation of bone repair compositions, and more special refers to a novel technology in preparing a matrix building polymer i.e. collagen with inclusions of hydroxyapatite particles as biomaterial for medical applications. In this composition that consists of hydroxyapatite particles embedded in a matrix at least 50% nm. Said composition is suitable as bone implant material, dental cement and for applications in wound healing. | 06-18-2009 |
| 20090155321 | COMPOSITIONS WITH ENCAPSULATED COLORING AGENTS AND METHOD TO IMPART A HEALTHY SKIN APPEARANCE - A cosmetic composition and method of imparting a healthy appearance to skin is provided which includes using a composition formed with about 0.1 to about 20% by weight of the composition of beads, from about 1 to about 80% by weight of the beads of a first coloring agent incorporated within a matrix of the beads, and a cosmetically acceptable carrier, the composition having a hue less than 25°, the beads being coated and having an exterior color other than that of the first coloring agent. | 06-18-2009 |
| 20090155322 | SELF-TANNING EFFECTS - A cosmetic composition and method is herein described for sunless tanning to impart a glow/shiny effect on skin. The composition includes a sunless tanning agent and coated beads incorporating tan colored pigment. A colorant which imparts a color other than tan to the beads is distributed within the coating. The cosmetic composition provides to the skin an immediate tan via the disintegrated beads. Sunless tanning agent acts more slowly and eventually will replace the pigment effect. The coating with colorant prevents the formula undesirably from appearing tan. Instead a color such as white renders the formula more aesthetically pleasing and more in line with the visuals paradigm of a moisturizer rather than a foundation. | 06-18-2009 |
| 20090155323 | SKIN COSMETIC COMPOSITION - A skin cosmetic composition comprising: a hydrogel particle comprising a non-crosslinked hydrogel containing an oil component therein dispersed in an aqueous medium; a hydrogel particle comprising a non-crosslinked hydrogel containing an oil component therein; and a process for preparing a hydrogel particle comprising the steps of discharging an oil component-emulsified or dispersed solution prepared by dissolving a non-crosslinked hydrogel in an aqueous solution, with vibration from an orifice to form droplets; and cooling the droplets to solidify. | 06-18-2009 |
| 20090155324 | Skin Treatment System - A skin treatment system includes a flexible panel having an outer surface and an inner surface. The flexible panel may be configured to surround at least a portion of a user's appendage. The skin treatment system may also include at least one skin treatment insert having an inner surface and an outer surface. The flexible panel may be further configured to releasably engage the skin treatment insert. The skin treatment insert may be configured to receive a topical skin treatment. The inner surface of the skin treatment insert may be configured to apply the topical skin treatment to at least a portion of a surface of the user's appendage. | 06-18-2009 |
| 20090155325 | FORMULATION AND PRODUCTS FOR PROMOTING SKIN CLEANLINESS AND HEALTH - The present disclosure generally relates to a formulation. More particularly, the formulation may be applied to skin and/or used in combination with a personal care product to improve absorbance and leakage control of the personal care product, and to promote a more positive feel and comfort through improved skin cleanliness and health. | 06-18-2009 |
| 20090155326 | LAYERED DRUG DELIVERY POLYMER MONOFILAMENT FIBERS - The present invention is directed generally to a layered polymeric monofilament fiber drug delivery device, where each layer of the device can contain a different polymer, drug, additive, or any combination or mixture thereof. The layered nature of the current monofilament polymeric monofilament device provides the capability to modulate the release of one or more drugs and/or the mechanical properties of the fiber so that drug release and device failure can be separately tuned to provide for the tailored introduction of therapeutically effective drugs or agents to a target tissue. Moreover, the fiber may comprise more than one distinct segments along its length, each segment itself having different combinations and/or numbers of layers thereby providing even greater freedom in the design of the therapeutic delivery device. The invention is also directed to a method of manufacturing such a layered polymeric monofilament fiber drug delivery device, and methods of treatment using such devices. | 06-18-2009 |
| 20090155327 | Self-Indicating Wipe for Removing Bacteria from a Surface - A wipe that includes a bacteriostatic agent that contains cations having an affinity for the negatively charged cell walls of bacteria is provided. The affinity of the bacteriostatic agent for the bacteria allows the wipe to capture bacteria, thereby removing them from a surface and also inhibiting their spread to other surfaces that may contact the wipe. Of particular advantage, the bacteriostatic agent may help protect against the spread or infection of pathogens without the use of chemicals, such as antiseptics or antibiotics. Still further, the wipe of the present invention also contains a solvatochromatic indicator that undergoes a color change in the presence of a broad spectrum of bacteria. Thus, when the wipe captures bacteria, the indicator undergoes a color change that signals to the user that the wipe is functioning properly. The lack of a color change may likewise provide the user with the assurance that the area is generally free of bacteria and clean. | 06-18-2009 |
| 20090155328 | FILMS COMPRISING ANTIMICROBIAL AND FUNGISTATIC AGENTS - A process for producing a film having incorporated or applied thereon or therein an antimicrobial agent and a liquid additive is provided wherein the film comprises a liquid absorbent layer and an impermeable layer are provided. The films can be used for producing a tubular casing or shrinkbag such as casings for foodstuffs. | 06-18-2009 |
| 20090155329 | Novel E. coli Bacteriophage and Uses Thereof - The present invention is directed to isolated | 06-18-2009 |
| 20090155330 | Vaccine Delivery via Microneedle Arrays - A microprojection array is provided, comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a vaccine and a polymeric material. The array may have multiple layers. The vaccine may be placed in only one layer. In another embodiment of the invention, a method of preventing a disease is provided, comprising insertion into the skin of a patient an array of microprojections comprising a layer which comprises a vaccine for that disease and a polymer. | 06-18-2009 |
| 20090155331 | INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS - Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine. | 06-18-2009 |
| 20090155332 | REPLACEMENT BONE TISSUE - Bone replacement tissue suitable for bone grafting procedures, said bone replacement tissue being grown in a host until suitable for translocation into a desired position in a patient, and methods for manufacturing said bone replacement tissue. | 06-18-2009 |
| 20090155333 | Dermis-Derived Cells for Tissue Engineering Applications - Methods for inducing differentiation of dermis-derived cells to serve as a source of chondrocytes and associated methods of use in forming tissue engineered constructs. One example of a method is a method for inducing differentiation of cells into chondrocytes comprising providing aggrecan sensitive isolated dermis cells and seeding the cells onto an aggrecan coated surface. | 06-18-2009 |
| 20090155334 | IMPLANT FOR TISSUE ENGINEERING - The invention provides a process for the production of a monolithic implant for use in tissue engineering, the process comprising the steps of plasticising at least one biocompatible material into a paste, extruding the paste through a die, and drying the extruded material to eliminate an aqueous and/or non-aqueous component. The invention also relates to a monolithic implant as thereby manufactured, and the use of such an implant as a scaffold for tissue-engineering and as a transplant tissue in reconstructive or replacement surgery. | 06-18-2009 |
| 20090155335 | NON-LEACHING NON-FOULING ANTIMICROBIAL COATINGS - Compositions containing one or more types of membrane-targeting antimicrobial agents immobilized on a substrate with activity in relevant biological environments, and methods of making and using thereof, are described herein. The antimicrobial agents retain their activity in the presence of blood proteins and/or in vivo due to improved molecular structures which allow for cooperative action of immobilized agents and hydrophilic chemistries which resist non-specific protein adsorption. Suitable molecular structures include branched structures, such as dendrimers and randomly branched polymers. The molecule structures may also include hydrophilic tethers which provide both flexibility and resistance to non-specific protein adsorption. The membrane targeting antimicrobial agent coatings can be applied to a variety of different types of substrates including medical implants such as vascular grafts, orthopedic devices, dialysis access grafts, and catheters; surgical tools, surgical garments; and bandages. The substrates can be composed of metallic materials, ceramics, polymers, fibers, inert materials such as silicon, and combinations thereof. The compositions described herein are substantially non-leaching, resistant to non-specific protein adsorption, and non-hemolytic. | 06-18-2009 |
| 20090155336 | NEUROMODULATORY METHODS FOR TREATING PULMONARY DISORDERS - A method for treating a pulmonary disorder in a subject includes inserting a therapy delivery device into a vessel of the subject, advancing the therapy delivery device to a point adjacent an intraluminal target site of the autonomic nervous system, and activating the therapy delivery device to delivery a therapy signal to the intraluminal target site to treat the pulmonary disorder. The intraluminal target site is in electrical communication with nervous tissue selected from the group consisting of a spinal nerve, a postganglionic fiber of a spinal nerve, a sympathetic chain ganglion, a thoracic sympathetic chain ganglion, a cervical ganglion, a lower cervical ganglion, an inferior cervical ganglion, an intramural ganglion, a splanchnic nerve, an esophageal plexus, a cardiac plexus, a pulmonary plexus, an anterior pulmonary plexus, a posterior pulmonary plexus, a celiac plexus, a hypogastric plexus, an inferior mesenteric ganglion, a celiac ganglion, and a superior mesenteric ganglion. | 06-18-2009 |
| 20090155337 | METHOD AND AGENT FOR IN-SITU STABILIZATION OF VASCULAR TISSUE - A method for stabilizing an extra cellular matrix layer in the vascular system of the body is disclosed herein. The method can comprise placing a vascular catheter adjacent to the extra cellular matrix layer, delivering a solution containing a bioflavonoid to the extra cellular matrix layer with the vascular catheter, and cross-linking protein in the extra cellular matrix layer. The bioflavonoid can be a catechin, particularly epigallocatechin gallate (EGCG). | 06-18-2009 |
| 20090155338 | Chronotherapeutic Ocular Delivery System Comprising a Combination of Prostaglandin and a Beta-Blocker for Treating Primary Glaucoma - Chronotherapeutic delivery system for treating primary open-angle glaucoma, comprising a delivery system incorporating pharmaceutical products for delivery to an eye in the treatment of primary open-angle glaucoma (POAG), comprising: (a) a biocompatible erodible material incorporating a therapeutically-effective amount of a prostaglandin analogue, and (b) a reservoir containing a therapeutically-effective amount of a beta-blocker, whereby, when the delivery system is placed in the eye the prostaglandin analogue is delivered gradually as the erodible material is eroded, and the beta-blocker is delivered rapidly when at least a predetermined portion of the erodible material has been eroded. | 06-18-2009 |
| 20090155339 | Biocompatible Antimicrobial Filament Material - The invention provides a biocompatible filament material having an antimicrobial finish, in particular in the form of a surficial layer, the finish comprising polyhexamethylenebiguanide (PHMB) as a nonspecifically antimicrobially active component, and also a process for producing the filament material, comprising the steps of:
| 06-18-2009 |
| 20090155340 | Method of cell storage in a delivery system - Cell storage and delivery systems and methods for storing and delivering viable cells to a mammal are disclosed. The cell storage and delivery systems include a biodegradable and/or bioabsorbable fibrous matrix physically associated with viable cells to contain and release the cells at a controlled rate. The biodegradable and/or bioabsorbable matrix can be formed by electrospinning fibers of biodegradable and/or bioabsorbable fiberizable material. The methods include methods for storing viable cells and for delivering viable cells to a mammal using the cell storage and delivery system. | 06-18-2009 |
| 20090155341 | Medical device and a method for applying a biochemically active material on one or more body parts - A medical device having a sleeve-shaped elastic body which is rolled up to form an annular structure and may be rolled down to annularly contacting one or more body parts, such as limbs, a biochemically active material, such as a disinfecting material, added substantially to a portion of the sleeve-shaped elastic body, and a pressure-exerting element for rolling down the sleeve-shaped elastic body while applying an external pressure on a contact point between the portion and the one or more body parts. | 06-18-2009 |
| 20090155342 | Mineral technologies (MT) for acute hemostasis and for the treatment of acute wounds and chronic ulcers - Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment of acute hemorrhage, are also provided. | 06-18-2009 |
| 20090155343 | Tamsulosin-Containing Transdermal Patch - A tamsulosin-containing transdermal patch. A transdermal patch comprising a backing-layer and an adhesive layer on the backing-layer, characterized in that the adhesive layer contains an acrylic adhesive, further contains tamsulosin as an active ingredient in an amount of 0.1 to 20% by mass of the total mass of the adhesive layer and, if desired, a polyoxyethylene alkyl ether which is an additive playing a role in increasing solubility and a propylene glycol fatty acid ester which is an additive playing a role in promoting percutaneous absorption is provided. Further, a transdermal patch comprising a backing-layer and an adhesive layer on the backing-layer, characterized in that the adhesive layer contains a synthetic rubber adhesive, further contains tamsulosin as an active ingredient in an amount of 0.1 to 20% by mass of the total mass of the adhesive layer and a propylene glycol fatty acid ester which is an additive playing a role in promoting percutaneous absorption is provided. | 06-18-2009 |
| 20090155344 | PREPARATION AND APPLICATION OF BIODEGRADABLE-MATERIAL-MADE MICROSPHERE VASCULAR EMBOLUS CONTAINING LIPOSOME-ENCAPSULATED CYTOKINES - The present invention discloses preparation and application of a kind of biodegradable-material-made microsphere vascular embolus that contains liposome-encapsulated cytokines. The present invention is technologically characterized by encapsulation of liposome-wrapped immunocytokines such as IL-2, TNF and interferon by sodium polysaccharide or gelatin, which is extracted from natural alga and is good at biodegradability and biocompatibility. Owing to the encapsulation procedures, cytokine microspheres can take shape measuring 50-75 μm, 75-150 μm, 100-200 μm, 200-300 μm, 200-450 μm, 100-300 μm, 300-500 μm, 500-700 μm, and 700-900 μm. The microsphere preparations are good targeting medication for embolism treatment and immunochemotherapy of animals loaded with human hepatocarcinoma and cervical cancer, as well as human suffering from late-stage or recurrent liver cancer, renal tumors, bladder cancer, colon carcinoma and rectal cancer. | 06-18-2009 |
| 20090155345 | METHODS FOR AFFECTING LIPOSOME COMPOSITION ULTRASOUND IRRADIATION - The present invention provides methods for loading of agents and substances into per-formed liposomes, preferably a suspension of pre-formed liposomes as well as to methods for the controlled quantum (step-wise) release of agents and substances from liposomes. One of the principle features of the methods of the invention is to expose the liposomes to ultrasound irradiation having predefined parameters, resulting in an increase in permeability of the liposomes, thereby permitting, respectively, the loading and/or release of agents and substances into and/or from the liposomes. | 06-18-2009 |
| 20090155346 | PREPARATION OF POWDERS CONTAINING COLLOIDAL PARTICLES - The invention discloses a method for preparing a powder from an aqueous liquid which comprises colloidal particles. The method is based on the use of dense-phase extraction media, i.e. near-critical or supercritical fluids. The powder obtained through the method can be reconstituted with an appropriate aqueous liquid to yield a colloidal dispersion. The method is particularly useful for drying and stabilising aqueous colloidal dispersions comprising an active compound, such as a drug substance. | 06-18-2009 |
| 20090155347 | Cosmetic Composition for Stimulating the Synthesis of Proteins of the Basement Membrane - Cosmetic composition which can be applied topically, comprising at least one compound of the general formula (I) in which R | 06-18-2009 |
| 20090155348 | Detoxified Recombinant Botulinum Neurotoxin - The present invention relates to the isolation of polypeptides derived from the | 06-18-2009 |
| 20090155349 | METHODS OF TREATING INFLUENZA VIRAL INFECTIONS - Methods are described for treating an influenza viral infection or associated diseases, disorders or mechanisms in a subject, comprising administering to the subject a therapeutically effective amount of a catecholic butane of the general formula (I) or a pharmaceutically acceptable salt thereof: | 06-18-2009 |
| 20090155350 | CHLAMYDIA ANTIGENS AND PROTEIN VACCINE - The present invention provides vaccines for immunizing a host, including humans, against disease caused by infection by a strain of | 06-18-2009 |
| 20090155351 | Solid Vaccine Formulation - The invention relates to a solid vaccine formulation adapted for mucosal administration comprising at least one antigen as active substance, wherein the formulation comprises a lyophilisate of a suspension comprising an oxygen-containing metal salt, the antigen(s) and one or more excipients selected from (i) saccharides, (ii) sugar alcohols, and (iii) amino acids or pharmaceutically acceptable salts thereof. | 06-18-2009 |
| 20090155352 | Microemulsion containing indolocarbazole compound and dosage forms containing the same - The invention described herein provides a pharmaceutical composition and oral dosage forms containing the same, having high concentrations of solubilized indolocarbazole compounds as the active ingredient in microemulsion form. The invention also provides a process for increasing the solubilized concentration of indolocarbazole compounds such as lestaurtinib using the addition of water in combination with a hydrophilic component as part of the microemulsion formation process. | 06-18-2009 |
| 20090155353 | MICROEMULSIONS FOR PHARMACEUTICAL COMPOSITIONS - The invention provides microemulsion pharmaceutical compositions comprising pharmaceutical actives which are hydrotropes that facilitate formation of microemulsions. The invention further provides methods of making the compositions and utilization of the compositions in liquid fill soft shell capsules including capsules having shells of non-animal derived materials (e.g. non-ADRM). | 06-18-2009 |
| 20090155354 | DISPENSING ENCAPSULATED LIQUIDS INTO BODY CAVITIES - Body tissue or cavities are treated by inserting a membrane module containing a substance for treating a condition of the cavity or tissue. The substance is enclosed in a membrane that melts, dissolves, or dissipates in the environment of the cavity such as a vagina to release the substance into the cavity. | 06-18-2009 |
| 20090155355 | Particles in a capsule - The invention relates to a capsule containing a heterogeneous mixture of active agents in the form of particles suspended in a liquid matrix and optionally active ingredients in the liquid matrix; the liquid matrix occupying less than the total internal volume of the capsule. The present invention further describes a capsule to allow the controlled-release of one or more active agents for specific desired benefits. | 06-18-2009 |
| 20090155356 | THIXOTROPIC OIL BASED VEHICLE FOR PHARMACEUTICAL COMPOSITIONS - The present invention relates to a novel thixotropic oily vehicle comprising between about 0.2% to about 5% (w/w) of a colloidal silica and between about 0.2% to about 5% (w/w) of a hydrophilic polymer in an edible oil. The interaction between the hydrophylic polymer and the colloidal silica in the above concentration ranges confers thixotropy and a low viscosity under shear on the solution. The invention also relates to capsules filled with the above thixotropic solution used as a fill mass. | 06-18-2009 |
| 20090155357 | Alcohol Resistant Pharmaceutical Formulations - The present invention provides alcohol resistant oral dosage pharmaceutical forms and methods of using such oral dosage forms to avoid dose dumping if the dosage form is taken together with alcohol. | 06-18-2009 |
| 20090155358 | PHARMACEUTICAL COMPOSITIONS OF SHORT-ACTING HYPNOTIC AGENTS IN MODIFIED-RELEASE FORMS AND THE PROCEDURES TO PREPARE THE MENTIONED FORMULATION - This application refers to a modified-release pharmaceutical composition containing, as the active agent, a short-acting hypnotic agent or a pharmaceutically acceptable salt thereof, comprising two sustained-release pharmaceutical entities, differentiated from each other by a different release rate of the active agent wherein the release of the active agent from one of the entities starts before the release of the active agent from the second entity. | 06-18-2009 |
| 20090155359 | GRANULATED PARTICLES, TABLETS AND METHOD FOR PRODUCING GRANULATED PARTICLES - The present invention relates to granulated particles including a poorly water soluble drug (A) and a diluent (B) and characterized in that a volume average particle size of the particles of the poorly water soluble drug (A) and the particles of the diluent (B) is within the range of 0.01 to 35 μm and a water soluble- or water swellable polymer compound (C) having a viscosity of less than 6.0 mPa·s in an aqueous solution thereof of 2% by mass at 20° C. is further contained, a tablet containing the granulated particles, and a method for producing the granulated particles. | 06-18-2009 |
| 20090155360 | ORALLY DISINTEGRATING TABLETS COMPRISING DIPHENHYDRAMINE - The compositions of the present invention comprise a therapeutically effective amount of particles consisting of diphenhydramine or pharmaceutically acceptable salts thereof, optionally in combination with another drug such as pseudoephedrine, or phenylephrine and hydrocodone, in combination with rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol and/or a saccharide. These compositions are useful in treating the symptoms of one or more diseases or conditions in which diphenhydramine (alone or in combination with one or two other drugs) is a therapeutically effective, e.g. allergic rhinitis, sinusitis, upper respiratory tract infections, motion sickness, Parkinson's disease, insomnia, the common cold, and nighttime pain management, particularly for subjects or patients with dysphagia, and people ‘on the move’. | 06-18-2009 |
| 20090155361 | TABLET WITH MULTIPLE DRUG-CONTAINING SECTIONS - A tablet which is either a two-layer tablet comprising a layer A and a layer B or a three-layer tablet comprising a layer A, a layer B and a layer C in that order, wherein the layer B is a medicinal additive layer, the layer A and the layer C are drug layers that are segmented on the layer B, and the sections of the layer A and the layer C are held on the layer B and contain either the same or different drugs. Also, a scored tablet wherein splitting at one of the score lines produces two fragments with equal drug contents and splitting at the other score line produces two fragments with unequal drug contents. In addition, a scored tablet wherein splitting at the score lines exposes cross-sections with different drug release-controlling functions. | 06-18-2009 |
| 20090155362 | Method of cross-linking hyaluronic acid with divinulsulfone - The present invention relates to methods of producing a homogenous hydrogel comprising hyaluronic acid, or salt thereof, crosslinked with divinylsulfone (DVS), said method comprising the steps of (a) providing an alkaline solution of hyaluronic acid, or salt thereof; (b) adding DVS to the solution of step (a), whereby the hyaluronic acid, or salt thereof, is crosslinked with the DVS to form a gel; (c) treating the gel of step (b) with a buffer, wherein the gel swells and forms a hydrogel comprising hyaluronic acid, or salt thereof, crosslinked with DVS. | 06-18-2009 |
| 20090155363 | METHODS FOR ORAL ADMINISTRATION OF ACTIVE DRUGS - The present invention relates to methods that facilitate the oral administration of active drugs to a patient. Specifically, the methods of the present invention may utilize compositions comprising an active drug and a gelling agent that provides an easily consumable gel dosage form and the active drug is homogenously mixed within the gel. | 06-18-2009 |
| 20090155364 | Transdiscal administration of anti-TNFalpha antibodies and growth differentiation factors - The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc. | 06-18-2009 |
| 20090155365 | Method for remotely controlling a sol-gel transition of hydrogels and method for delivering a drug using the same - The present invention relates to a method for remotely controlling a sol-gel transition of hydrogels and a method for delivering a drug using the same. More specifically, the invention relates to a method of remotely controlling a sol-gel transition of polyethylene glycol (PEG)-containing hydrogels—three-dimensional networks of crosslinked polymer chains—by X-ray irradiation, and relates to a method for delivering a drug using the same. | 06-18-2009 |
| 20090155366 | OSTEOINDUCTIVE MATERIALS - The present invention concerns improved osteoinductive materials comprising matrix materials and morphogenetic roteins, wherein depending on the subject matter the proteins may be dimeric or monomeric proteins. The osteoinductive materials according to the present invention have improved properties. The invention further concerns methods for producing the respective improved osteoinductive materials. | 06-18-2009 |
| 20090155367 | Occlusion of Fallopian Tubes - The present invention provides a method for inducing Fallopian tube blockage as a means for female contraception. The method comprises contacting the inner surface tissue of a Fallopian tube with a silver nitrate bearing substrate, delivering an amount of silver nitrate to the tissue sufficient to induce blockage of the Fallopian tube. Preferably, the substrate is a bead. In one embodiment, at least one silver nitrate bearing bead is introduced through the uterine opening of the Fallopian tube by use of a catheter or other device suitable for manipulating the bead. Alternatively, a plurality of beads can be introduced into the Fallopian tube. In a preferred embodiment, one or more silver nitrate bearing beads are arranged on a string to facilitate later removal of the beads. The method of the present invention delivers an amount of silver nitrate to the tissue sufficient to cause tissue necrosis and blockage of the Fallopian tube. The silver nitrate is delivered to the tissue by the substrate in a controlled and localized manner. | 06-18-2009 |
| 20090155368 | Pharmaceutical compositions - The present invention relates to crosslinked polyamine particles and/or pharmaceutical compositions comprising, at least in part, crosslinked polyamine particles and aggregates of such particles (including cured aggregates of crosslinked polyamine particles). The compositions may be in the form of tablets comprising, for example, particles larger than 500 μm, and used for treating patients, for example, patients with hyperphosphatemia. | 06-18-2009 |
| 20090155369 | PHARMACEUTICAL COMPOSITION CONTAINING LEVODOPA, ENTACAPONE AND CARBIDOPA - The present invention refers to a solid pharmaceutical composition of entacapone, levodopa and carbidopa or pharmaceutically acceptable salts thereof characterized in that entacapone is in the form of granules and it is added separately to levodopa and carbidopa. In addition, this invention provides the process for its preparation. | 06-18-2009 |
| 20090155370 | METHODS AND COMPOSITIONS FOR SELECTIVELY REMOVING POTASSIUM ION FROM THE GASTROINTESTINAL TRACT OF A MAMMAL - The present invention provides methods and compositions for the treatment of ion imbalances using core-shell composites and compositions comprising such core-shell composites. In particular, the invention provides core-shell particles and compositions comprising potassium binding polymers, and core-shell particles and compositions comprising sodium binding polymers, and in each case, pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are also disclosed. The compositions and methods of the invention offer improved approaches for treatment of hyperkalemia and other indications related to potassium ion homeostasis, and for treatment of hypertension and other indicates related to sodium ion homeostasis. | 06-18-2009 |
| 20090155371 | Compositions Comprising Solid Particles Entrapped In Collapsed Polymeric Microspheres, And Methods Of Making The Same - The present invention relates to topical compositions containing solid particles that are stabilized via entrapment by microspheres. Each of the microspheres contains a collapsed polymeric shell that has entrapped therein one or more solid particles. The solid particles are preferably formed of zinc oxide or titanium dioxide or both, which can readily be used either alone or in combination with other sunscreen agents to form sunscreen compositions of broader UV protection spectrum and enhanced photostability. | 06-18-2009 |
| 20090155372 | METHOD OF MANUFACTURING MODIFIED RELEASE DOSAGE FORMS - In one embodiment a dosage form comprises at least one active ingredient and a molded matrix which comprises 10-100% of a material having a melting point of less than about 100 degrees C. selected from the stamp consisting of thermoplastic polyalkylene oxides, low melting hydrophobic materials, thermoplastic polymers, thermoplastic starches and combinations thereof, and the matrix is capable of providing modified release of the active ingredient upon contacting of the dosage form with a liquid medium. The dosage form may additionally comprise uncoated particles which may contain at least one active ingredient. In another embodiment, a dosage form comprises at least one active ingredient, a plurality of particles and a molded matrix, wherein at least a portion of the particles are coated. The coated particles, the matrix or both may comprise at least one active ingredient, and the coated particles or the matrix or a combination thereof is capable of providing modified release of the active ingredient upon contacting of the dosage form with a liquid medium. | 06-18-2009 |
| 20090155373 | COSMETIC COMPOSITIONS AND METHOD WHICH IMPART A HEALTHY APPEARANCE TO SKIN - A cosmetic product and method of imparting a healthy appearance to skin is provided which includes using a composition formed with about 0.1 to about 20% by weight of the composition of beads, from about 1 to about 80% by weight of the beads of a coloring agent incorporated within a matrix of the beads, and a cosmetically acceptable carrier, the composition being delivered from a package with instructions being printed on or associated with the package indicating topical use on skin to impart a healthy appearance, and wherein the skin with the applied composition has a reflectance in the range from 510 to 600 nm, and reflectance amplitude ratios at wavelength 510/540 nm ranging from 1.10 to 1.20 and at wavelength 600/580 nm ranging from 1.35 to 1.65. | 06-18-2009 |
| 20090155374 | Nanoparticles for protein drug delivery - The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery. | 06-18-2009 |
| 20090155375 | Compositions comprising a lipid and copolymer of styrene and maleic acid - A composition comprising a lipid and copolymer of styrene and maleic acid, wherein the copolymer of styrene and maleic acid is non-alternating, and wherein the polymer and lipid are in the form of macromolecular assemblies. | 06-18-2009 |
| 20090155376 | PROTEIN HYDROLYSATE WITH ANTIDIABETIC EFFECT - The present invention provides compositions (blood sugar increase inhibitors) that have an action of lowering the blood sugar level of a subject in a hyperglycemic condition and are for use in lowering the blood sugar level of such a subject. Moreover, the present invention provides compositions for use in preventing or treating diseases resulting from hyperglycemia, in particular, diabetes and diabetic complications, due to the aforementioned action (a preventive or ameliorative composition for diseases resulting from hyperglycemia, an antidiabetic agent). | 06-18-2009 |
| 20090155377 | Synergistic Phytoceutical Compositions - Phytoceutical compositions for the prevention and treatment of circulatory disorders, feminine endocrine disorders, and dermal disorders. A specific combination of extracts of plants is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants from each group. Such combinations have synergistic effects, with minimal side effects. | 06-18-2009 |
| 20090155378 | OSTEOINDUCTIVE DEMINERALIZED CANCELLOUS BONE - An osteoinductive demineralized bone matrix, corresponding osteoimplants, and methods for making the osteoinductive demineralized bone matrix are disclosed. The osteoinductive demineralized bone matrix may be prepared by providing demineralized bone and altering the collagenous structure of the bone. The osteoinductive demineralized bone matrix may also be prepared by providing demineralized bone and compacting the bone, for example via mechanical compaction, grinding into a particulate, or treatment with a chemical. Additives such as growth factors or bioactive agents may be added to the osteoinductive demineralized bone matrix. The osteoinductive demineralized bone matrix may form an osteogenic osteoimplant. The osteoimplant, when implanted in a mammalian body, may induce at the locus of the implant the full developmental cascade of endochondral bone formation including vascularization, mineralization, and bone marrow differentiation. The osteoinductive demineralized bone matrix may also be used as a delivery device to administer bioactive agents. | 06-18-2009 |
| 20090155379 | Nutritional composition for facilitating muscle pumps - A composition for providing a method for creating and prolonging muscle pumps, providing a transducer effect for nitric oxide, increasing nutrient delivery and promoting increased vascular response in individuals. The composition of the present invention comprises citrulline, aspartic acid and creatine. In addition, the nutritional composition may also comprise L-arginine, and maritime pine (bark) extract. The nutritional composition of the present invention may also further comprise L-leucine and L-valine. | 06-18-2009 |
| 20090155380 | Non-medicinal food additive for animals, supplemented foods containing same and method for improving animal growth - This invention relates to a non-medicinal food additive that is an animal growth promoter containing 99% pure zeolite partially or totally exchanged with a C | 06-18-2009 |
| 20090155381 | Method of treatment or prevention of age-related macular degeneration - A method of treatment and/or prevention of age-related macular degeneration (AMD) wherein, in a first step, the need for treatment or susceptibility to AMD is determined for an individual and, in a second step, a medication comprising lutein and/or zeaxanthin and/or certain antioxidants (or a mixture thereof) is tailored to that individual. The invention also provides a method of determining a substance to be administered to an individual, which individual may be susceptible of having age-related macular degeneration (or an age-related macular degeneration-related disorder) comprising: a) determining the susceptibility of the individual to age-related macular degeneration (usually genetically, by detection of an SNP); and b) on the basis of the determination in a), identifying a substance capable of preventing or treating age-related macular degeneration in that individual. The method may additionally comprise providing (such as administering or communicating) the substance (or its identity) to the individual. | 06-18-2009 |
| 20090155382 | Methods and Compositions for Heavy Metal Detoxification - Compositions and methods for enhancing heavy metal detoxification are described. The compositions and methods described provide enhanced activity of key detoxification systems including that the induction of phase II detoxification enzymes, such as glutathione S-transferases (GSTs), and NADPH quinone reductase (NQO1) activity. | 06-18-2009 |
| 20090155383 | Personal Care Compositions Comprising Undecyl Sulfates - A personal care composition utilizing undecyl sulfates and/or ethoxylated undecyl sulfates (undeceth sulfates). | 06-18-2009 |
